We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
New measures to commence 1 January 2025.
Kieron Banks (34) was sentenced today at the Nightingale Court in Wolverhampton for the illegal possession and intent to supply prescription-only medication valued at over £2m following investigations by the Medicines and He…
The new COVID-19 vaccine from SK Chemicals, has been authorised after meeting the MHRA’s required safety, quality and effectiveness standards.
The MHRA has today launched a public consultation on the revised ICH guideline on Good Clinical Practice.
The Innovative Devices Access Pathway (IDAP), set for launch later in 2023, will be operated by the Medicines and Healthcare products Regulatory Agency (MHRA), the National Institute for Health and Care Excellence (NICE), He…
The new recognition routes open additional options for the MHRA to bring cutting-edge medicines faster to UK patients by leveraging the expertise and decision-making of trusted regulatory partners
A brand-new challenge for artificial intelligence and machine learning developers, to build models that can predict heart failure-related health outcomes for veterans has been launched by a collaboration between regulators a…
The Medicines and Healthcare products Regulatory Agency (MHRA) has today announced it will be the first drug safety regulator in the world to pilot its own genetic ‘biobank’, launching 1 June 2023
Following a public consultation and the review of a reclassification application from the manufacturer, the MHRA has decided that Aquiette 2.5mg Tablets will remain a prescription-only medicine.
Patients, or carers of patients, who carry Emerade 300 or 500 microgram adrenaline auto-injector pens should contact their GP and obtain a prescription for, and be supplied with an alternative brand. They should then return …
The COVID-19 vaccine from Moderna has met the MHRA’s required safety, quality and effectiveness standards to be authorised for use in this age group
The European Parliament has voted to adopt an extension of the transition period for the EU Medical Device Regulations and to extend the validity of certain device certificates
CE marked medical devices to be accepted in Great Britain for a longer period.
The Department of Health and Social Care has today announced the reappointment of two Non-Executive Directors of the MHRA from 1 September.
Following an expert safety review of isotretinoin, the Commission on Human Medicines has agreed to a number of recommendations to strengthen the safe use of the treatment.
After almost 8 years as a Board Member, Stephen has decided to step down on 11 July 2023.
The Access Consortium is offering joint pipeline meetings to pharmaceutical and biotechnology companies.
Findings from research by the MHRA have been published, evaluating two different approaches to cancer therapies which harness the immune system to determine which better targets cancer cells and would reduce side effects for…
Guidance in relation to Regulation 238 of the Human Medicines Regulations 2012
Changes have been designed to ensure the agency is resourced to provide patients, the public and industry with the service they deserve and expect.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.